Seagen says clinically meaningful PFS observed in Phase 2 ADCETRIS study

Seagen announced that clinically meaningful progression-free survival, a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma. This is the first time 12-month PFS results were presented for the treatment combination, which avoids use of vinblastine and bleomycin in patients with early stage cHL. Results from the trial, called SGN35-027, were presented in an oral session at the 65th American Society of Hematology Annual Meeting & Exposition in San Diego.